ONCAlert | 2017 San Antonio Breast Cancer Symposium

An Overview of the CALGB 10603 Trial in AML

Richard Stone, MD
Published Online:1:10 PM, Fri August 5, 2016


Richard M. Stone, MD, Program Director, Adult Leukemia Program, Dana-Farber Cancer Institute, discusses the CALGB 10603 (RATIFY) trial, which explored the use of midostaurin (PKC412) as a treatment for patients with FLT3-mutated acute myeloid leukemia (AML).
Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.